Articles tagged with Autoimmunity
NIK kinase's non-canonical NF-κB pathway is crucial for immune development and function, while its NF-κB-independent functions regulate cellular metabolism and mitochondrial health. Dysregulation of NIK is linked to various diseases, making it a promising therapeutic target.
Researchers discover enzyme ANKIB1 crucial for innate immune signalling, driving type I and type III interferon induction. This finding solves a long-standing puzzle in innate immunity and provides opportunities for new therapies for devastating diseases.
Researchers found that macrophages retain memories of previous infections due to persistent signaling molecules left behind, which can be reversed by blocking cytokine signaling pathways. This discovery suggests new ways to reduce the activity of misprogrammed macrophages contributing to autoimmune diseases.
Research reveals molecular interaction between environmental and genetic risk factors triggers MS. EBV and gene variants HLA-DR15 haplotype play key roles in disease onset.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Researchers at Gladstone Institutes and UCSF have identified the genetic switches that regulate FOXP3 levels in human and mouse cells. In humans, multiple enhancers work together to keep FOXP3 active, while a repressor keeps it off in conventional T cells. This discovery has important implications for developing immune therapies.
Researchers at UMC Utrecht are developing a predictive model to accurately predict disease progress in juvenile dermatomyositis. The Interferon Score aims to identify which children can safely reduce medication and which require intensified treatment.
Researchers at CU Anschutz discovered a genetic program within lymphatic endothelial cells that enables storage and archival of antigens, helping the immune system remember infections. This understanding could lead to improved vaccines and therapies by fine-tuning immune memory.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
Researchers at the University of Chicago discovered that random fluctuations in gene expression enable certain cells to express genes from other tissues, promoting immune system training and tissue repair. This 'epigenetic noise' can also contribute to cancer development by allowing cancer cells to access a broader range of genes.
Scientists have created a detailed map of cell behavior in the small intestine of people with coeliac disease using single-cell RNA sequencing. The study found that immune signals from immune system proteins encourage fibroblasts to support changes in the gut lining, suggesting communication between cells plays a key role in the disease.
Researchers discovered LAG-3 inhibits T cell activity through spatial proximity to TCR, not ligand binding. This discovery enables precise modulation of autoreactive T cells in autoimmune diseases.
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
Moleculera Biosciences, a precision medicine company, is attracting investors with its technology developed by the University of Oklahoma. The company's diagnostic tests have helped properly diagnose over 16,000 patients and have shown remarkable recoveries in those affected by autoimmune disorders.
Scientists have identified COVID-derived molecular mimics that trigger autoimmunity, with some associated with type 1 diabetes and multiple sclerosis. The study suggests people with specific genetics may be at higher risk of COVID-induced autoimmunity.
Research from the University of Chicago shows that a specially trained population of immune cells, called peacekeeper cells, prevents other immune cells from attacking their own cells during infection. This specificity allows the immune system to distinguish between foreign and self-antigens, preventing autoimmune attacks.
A study found that misdiagnoses of autoimmune diseases like lupus and vasculitis can lead to increased depression, anxiety, and lower mental wellbeing in patients. Clinicians are calling for greater awareness and support for patients affected by these misdiagnoses.
La Jolla Institute scientists found that a protein in brain cells drives Parkinson's onset and may explain why the disease is more common in men. PINK1 appears to mark brain cells for immune cell attack, leading to inflammation and death.
Researchers have developed two therapeutic cocktails that inhibit key molecules, stopping immune cells from overreacting to allergens. The treatments reduced asthma attacks in mice by erasing the immune system's memory of asthma-causing allergens.
A new study published in the Journal of Crohn's and Colitis reveals that vancomycin may be an effective treatment for people with inflammatory bowel disease (IBD) and autoimmune liver disease. The antibiotic achieved clinical remission in 80% of patients, with significant decreases in inflammatory markers and mucosal healing.
A natural compound derived from gut-friendly bacteria significantly slows vitiligo progression and may restore pigmentation in mice. The findings could offer hope to millions affected by the autoimmune disease, which causes visible patches of skin discoloration and carries profound emotional and physical consequences.
Researchers at Garvan Institute of Medical Research discovered how chronic hepatitis C infection leads to autoimmune disease by identifying 'rogue clone' B cells with harmful autoantibodies. The study found that a triad of genetic mutations is required for the autoimmune disease to develop, opening new paths for treatments.
Researchers found that cellular RNA molecules help regulate antiviral signaling by activating the MAVS signalosome. This signaling pathway is crucial for coordinating immune responses against virus invasion. The study's findings suggest a potential role for RNA-based therapeutics in combating infections and autoimmune diseases.
Women with infertility are at higher risk of developing SARD, including lupus and Sjögren's syndrome, even after accounting for pre-eclampsia and other pregnancy complications. Infertility treatments do not appear to increase this risk, suggesting that women may be undiagnosed or untreated.
A scoping review found associations between myositis disease activity and gluten exposure in patients with inflammatory myopathies and celiac disease. The study suggests that gluten may act as an exogenous antigen driving myositis in genetically predisposed patients.
Recent advancements in AIH pathogenesis have paved the way for novel therapeutic strategies, including treatments targeting the gut-liver axis and immune system dysregulation. Emerging biologics and immune-modulating drugs show promise in achieving biochemical remission in refractory cases.
A retrospective cohort study found associations between COVID-19 and the long-term risk of various autoimmune and autoinflammatory connective tissue disorders. Long-term monitoring and care are crucial to mitigate these risks, taking into account demographic factors, disease severity, and vaccination status.
A McGill University study reveals that vitamin D deficiency early in life can lead to a higher risk of autoimmune diseases like Type 1 diabetes. The research found that an aging thymus causes the immune system to become less effective, increasing the risk of misdirected immune cells attacking healthy tissues.
Researchers found Itaconate stimulates immune cells to produce anti-viral proteins called interferons by blocking an enzyme called SDH, offering a potential therapy for autoimmune and infectious diseases.
Women with recurrent pregnancy loss and anti-β2-glycoprotein I/HLA-DR autoantibodies who received low-dose aspirin or heparin treatment had significantly improved outcomes, with 87% experiencing live births and a reduced risk of complications. The treatment was also effective for women with only the newly discovered antibodies.
A large study found that women with premature ovarian insufficiency are 2.6 times more likely to have an autoimmune disorder, with some conditions increasing the risk by 26 times. The study suggests a strong link between POI and severe autoimmune diseases, highlighting the need for medical professionals to be aware of this increased risk.
Researchers discovered that disrupting plant microbiomes can compromise a plant's immune system, leading to autoimmunity. Prebiotics could potentially support or reset the microbiome to maintain balance, reducing losses in food crops.
This study found modestly increased risks of inflammatory bowel disease and bullous skin disorders in hospitalized patients infected with the Omicron variant. Booster vaccination mitigated long-term autoimmune sequelae risk.
Recent research highlights gluten's role in inducing harmful immune responses in chronic inflammatory diseases, including celiac disease and other autoimmune conditions. Gluten withdrawal can alleviate symptoms, while a gluten-free Mediterranean diet may be a healthier alternative for overall nutritional adequacy.
Researchers have discovered several rare types of helper T cells associated with immune disorders such as multiple sclerosis and rheumatoid arthritis. The study found that genetic variants in bidirectional enhancer DNA are linked to specific immune-mediated diseases, including inflammatory bowel disease.
Researchers found that a drug approved to treat autoimmune diseases and cancers alleviated symptoms of APS-1, a rare genetic syndrome caused by elevated interferon-gamma. Ruxolitinib, a Janus kinase inhibitor, normalized IFN-gamma responses and reduced AP-1-related symptoms in study participants.
Scientists at Gladstone Institutes used CRISPR interference to map the layered mechanisms controlling expression of key immune genes. The study provides valuable insights into immune balance, autoimmunity, and cancer immunotherapies, shedding light on genetic variants linked to disease risk and potential treatments.
The study, conducted by Children's Hospital Colorado, found improvements in symptoms and quality of life for children diagnosed with celiac disease after participating in a mass screening program. Mass screening for pediatric celiac disease may become more common in the US, following similar conclusions drawn from European studies.
Researchers have developed a novel immunotheraphy targeting macrophages to induce tolerance in type 1 diabetes, demonstrating its potential as a curative treatment. The therapy also shows promise for other autoimmune diseases, with results suggesting no impact on the immune system's ability to capture and process liposomes.
A novel antibody constant region variant (REW) extends plasma half-life and improves biodistribution, allowing for both invasive and non-invasive delivery. The REW technology also enhances the complement system, providing enhanced ability to kill cancer cells and bacteria.
ISB researchers identify NKG2A-biased immune responses as protective against decreased inflammation and increased survival rates in various disease contexts. The study suggests potential therapeutic targets for modifying immune responses across diseases.
Researchers developed scSNV-seq to investigate genetic changes affecting gene activity and disease development. The technique accurately assesses the impact of thousands of DNA mutations in cells, providing crucial insights for developing targeted therapies.
Researchers found that X-chromosome inactivation can lead to autoimmune disorders, but other factors also cause them. The study suggests that the unique combination of proteins generated during this process may trigger a strong immune response, increasing the risk of autoimmunity in women.
A new mechanism of vestibular neuritis has been discovered, linking it to autoimmunity and the presence of anti-GQ1b antibodies. The study found that these antibodies were associated with bilateral vestibular damage in 33% of patients, and improved upon conversion to negative, suggesting a potential for immunotherapy.
A study by researchers at the Medical University of Vienna found that natural killer cells may play a crucial role in protecting against multiple sclerosis (MS) disease. The investigation revealed that strong EBV-specific and autoreactive immune responses combined with poor autoimmunity control increase MS risk.
Salk researchers identify Foxp3 as the protein that determines regulatory T cell genome structure and fate, enabling manipulation to treat autoimmunity or fight cancer. The study reveals Foxp3's essential role in creating unique chromatin architecture of regulatory T cells.
Researchers discovered a cell signaling pathway that allows effector memory T cells to drive innate cytokine storms in autoimmune diseases. Targeting the STING pathway may prevent inflammation chain reactions, offering new hope for treating conditions like type 1 diabetes and rheumatoid arthritis.
Researchers identified TLR9 as a key receptor in central tolerance, the process that eliminates self-reactive B cells. Depleting TLR9 impairs this process, leading to increased antibody production and autoimmune disease. Neutralizing CXCL4 may restore B cell tolerance, offering new therapeutic strategies.
Researchers found that mothers' bodies retain a long-term supply of immune suppressive T cells that recognize the next fetus by the same couple, instructing the rest of the immune system to stand down. This 'memory' effect persists in women even after childbirth.
Patients with vitiligo show a 25% decreased risk of mortality compared to controls, suggesting an autoimmune protective effect. The study found lower mortality rates for patients with vitiligo due to cancer and other causes, offering new avenues for research into mechanisms underlying this protective effect.
A study published in NPJ Aging reveals that COVID-19 exacerbates production of auto-antibodies associated with blood clotting disorders and aging. Researchers found that severe COVID-19 cases display a significant age-related increase in auto-antibodies, which can lead to tissue injury and organ damage.
Researchers at Brigham and Women's Hospital have designed a probiotic to suppress autoimmunity in the brain, which is at the core of several diseases including MS. The treatment offers a more precise way to target brain inflammation with reduced negative side effects compared to standard therapies.
A Scripps Research study has developed a method to analyze T cells in blood samples to detect early signs of autoimmune disease that could lead to type 1 diabetes. This approach has shown 100% accuracy in identifying at-risk patients and may be used for personalized treatment.
The new Clinical Research Unit will investigate autoantibodies' role in neurological disorders, focusing on diagnosis and treatment. Researchers expect innovative therapies for patients with previously suspected diseases.
A recent study has elucidated the genetic factors involved in systemic lupus erythematosus (SLE) development. The researchers found that HLA-DRB1*15:01 is primarily associated with SLE development in the Japanese population, suggesting its role in influencing disease progression. Furthermore, the study highlights the importance of anal...
Researchers identify altered proteins predicting islet autoimmunity, a precursor to Type 1 diabetes. The findings mark an important step forward in predicting the disease months before symptoms appear.
Cartesian Therapeutics has successfully treated patients with generalized myasthenia gravis using an RNA CAR-T therapy. The trial demonstrated marked and long-lasting clinical improvement, with three patients achieving complete or near-complete eradication of disease symptoms.
A study published in Brain Behavior and Immunity found autoantibodies against a synaptic adhesion protein, neurexin 1α, in patients with schizophrenia. In mice, these autoantibodies caused schizophrenia-related changes, including reduced social behavior and cognitive function.
A new study found that canagliflozin, a type 2 diabetes drug, can dampen down T-cell activation, suggesting it could be repurposed to treat certain autoimmune diseases. This discovery provides a potential therapeutic route for patients with autoimmune disorders.
Researchers at UCLA Jonsson Comprehensive Cancer Center have found a potential therapeutic target, IL-21, to reduce endocrine autoimmune side effects from checkpoint immunotherapy. A specific group of immune cells play a central role in this autoimmune attack and blocking IL-21 prevents thyroid autoimmunity.